Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 1.9a

Immunosuppression Use by Organ in 2008 and 2009

  Organ
Heart-Lung Heart Intestine Kidney KP Liver Lung PAK PTA
Transplants (2009) 29 2,212 180 16,830 854 6,320 1,661 198 181
Tx With Immunosuppression Info at Discharge 27 2,157 175 16,546 834 6,192 1,627 192 174
Induction Drug Reported 55.6% 54.3% 58.3% 84.0% 87.4% 25.9% 61.3% 82.8% 78.2%
Induction Drugs Atgam/NRATG/NRATS 7.4% 6.5% 1.1% 1.5% 1.7% 0.7% 6.6% 0.0% 1.7%
OKT3 0.0% 1.8% 21.1% 1.2% 1.4% 2.4% 0.7% 1.0% 13.2%
Thymoglobulin 0.0% 17.4% 41.7% 47.5% 63.1% 9.4% 5.1% 61.5% 59.2%
Zenapax 29.6% 13.2% 4.0% 10.1% 5.3% 6.5% 15.9% 3.1% 2.9%
Simulect 14.8% 15.0% 1.7% 15.7% 10.1% 8.7% 26.7% 7.8% 4.0%
Campath 3.7% 3.6% 12.0% 12.8% 11.2% 0.7% 7.8% 11.5% 12.6%
Tx With Immunosuppression Info and Functioning Graft at Discharge 24 2,060 154 16,293 821 5,909 1,547 178 161
Maintenance at Discharge Corticosteroids Use Steroids 100.0% 88.7% 64.9% 66.9% 69.9% 81.3% 98.2% 59.6% 44.1%
Calcineurin Inhibitor Use Cyclosporine 16.7% 18.7% 0.0% 5.7% 3.4% 7.0% 7.8% 3.9% 1.2%
Tacrolimus 87.5% 78.6% 98.7% 89.7% 94.0% 88.8% 88.8% 93.8% 97.5%
Everolimus 4.2% 0.5% 0.0% 0.5% 0.5% 0.4% 0.5% 0.0% 0.0%
Antimetabolite Use Mycophenolate Mofetil 75.0% 85.2% 35.7% 69.3% 64.7% 66.2% 50.9% 73.6% 59.6%
Mycophenolate Sodium 0.0% 3.7% 0.0% 22.4% 25.9% 8.1% 7.4% 20.8% 5.6%
Azathioprine 16.7% 3.1% 0.0% 0.6% 0.7% 1.2% 29.5% 0.6% 0.0%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
mTOR Inhibitor Use Sirolimus 0.0% 1.4% 2.6% 2.9% 6.1% 2.1% 0.4% 7.3% 14.3%
Everolimus 0.0% 0.5% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0%
Transplants (2008) 27 2,163 185 16,521 837 6,319 1,478 213 223
Tx With Maintenance Use at 1yr PostTx 15 1,783 137 14,692 745 4,898 1,145 165 159
Maintenance at 1yr PostTx Corticosteroids Use Steroids 100.0% 60.0% 68.6% 65.6% 72.1% 34.4% 99.0% 63.0% 52.8%
Calcineurin Inhibitor Use Cyclosporine 20.0% 21.3% 0.7% 7.6% 5.2% 8.5% 10.0% 6.1% 0.6%
Tacrolimus 73.3% 74.9% 97.1% 86.3% 91.8% 83.7% 86.0% 86.1% 98.7%
Everolimus 0.0% 0.5% 0.0% 0.5% 0.1% 0.4% 0.7% 0.6% 0.0%
Antimetabolite Use Mycophenolate Mofetil 53.3% 72.4% 13.9% 63.1% 54.9% 44.1% 47.4% 64.8% 51.6%
Mycophenolate Sodium 0.0% 6.6% 0.0% 22.7% 29.3% 5.7% 9.2% 17.0% 10.7%
Azathioprine 26.7% 5.7% 0.7% 1.7% 1.2% 0.9% 20.9% 4.2% 0.0%
Leflunomide 0.0% 0.0% 0.0% 1.2% 0.8% 0.0% 0.3% 0.6% 0.0%
mTOR Inhibitor Use Sirolimus 6.7% 7.2% 8.8% 6.7% 10.3% 7.0% 5.8% 13.3% 13.2%
Everolimus 0.0% 1.2% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.